Tratamento da Insônia com Zolpidem

Eficácia e Segurança

• O zolpidem demonstrou eficácia no tratamento da insônia tanto de início quanto de manutenção do sono, com evidências de qualidade moderada a baixa mostrando melhora na latência do sono, tempo total de sono e despertares noturnos 1
• A Academia Americana de Medicina do Sono recomenda o zolpidem como um dos agentes de primeira linha para o tratamento da insônia 2

Perfil de Segurança

• Os benzodiazepínicos de ação intermediária e longa (como lorazepam) são caracterizados por meia-vida superior a 24 horas, metabólitos farmacologicamente ativos, acúmulo com doses múltiplas e depuração prejudicada em pacientes idosos e com doença hepática 3

Risco de Dependência e Tolerância

• Os benzodiazepínicos tradicionais têm maior potencial para desenvolver tolerância, dependência física e síndrome de abstinência mais grave quando comparados ao zolpidem 4, 5
• A Associação Médica de Alberta não recomenda benzodiazepínicos de ação intermediária e longa (como lorazepam) para insônia devido aos riscos de efeitos adversos e dependência 3

Considerações para Populações Específicas

• Em idosos, o zolpidem em dose reduzida (5mg) é considerado mais seguro que benzodiazepínicos tradicionais devido ao menor risco de quedas e comprometimento cognitivo residual 1
• Para pacientes com histórico de transtornos por uso de substâncias, o zolpidem ainda apresenta riscos, mas pode ser preferível aos benzodiazepínicos tradicionais que têm maior potencial de abuso 6

Abordagem Recomendada para o Tratamento da Insônia

• A terapia cognitivo-comportamental para insônia (TCC-I) deve ser considerada o tratamento de primeira linha para insônia crônica, antes ou em conjunto com o tratamento farmacológico 7
• Quando o tratamento farmacológico é necessário, os hipnóticos não-benzodiazepínicos como zolpidem são preferidos sobre benzodiazepínicos tradicionais 2
• O tratamento farmacológico deve ser usado pelo menor tempo possível e na menor dose eficaz, com reavaliação regular da necessidade de continuação 1, 3

Tratamento da Insônia

Recomendações para o Tratamento Farmacológico

• A American Academy of Sleep Medicine recomenda que a sequência de tratamento farmacológico para insônia primária comece com agonistas de receptores benzodiazepínicos de curta a intermediária ação ou ramelteon 8, 9, 10
• A segunda linha de tratamento inclui agonistas alternativos de BzRAs de curta a intermediária ação ou ramelteon, se o agente inicial não foi bem-sucedido 8, 9
• A terceira linha de tratamento inclui antidepressivos sedativos, especialmente quando usados em conjunto com o tratamento de depressão/ansiedade comórbidas 8, 9, 11
• A quinta linha de tratamento inclui outros agentes sedativos, incluindo medicamentos antiepilépticos e antipsicóticos atípicos, como a quetiapina, apenas para pacientes com insônia comórbida que possam se beneficiar da ação primária desses medicamentos 8, 9

Abordagem Recomendada para Insônia

• A terapia cognitivo-comportamental para insônia (TCC-I) é uma terapia eficaz e recomendada no tratamento da insônia crônica 9
• Outras terapias comportamentais incluem restrição de sono, intenção paradoxal e biofeedback 9
• O tratamento hipnótico de curto prazo deve ser complementado com terapias comportamentais e cognitivas quando possível 8, 9

Considerações Importantes para o Uso de Medicamentos para Insônia

• O tratamento farmacológico deve ser acompanhado por educação do paciente sobre metas e expectativas de tratamento, preocupações de segurança, e potenciais efeitos colaterais 8, 9
• Os pacientes devem ser acompanhados regularmente para avaliar a eficácia, possíveis efeitos colaterais e a necessidade de medicação contínua 8, 9
• Deve-se empregar a menor dosagem eficaz de manutenção e reduzir gradualmente a medicação quando as condições permitirem 8, 9

Olanzapine for Insomnia Treatment

Evidence Against Olanzapine for Primary Insomnia

• The American Academy of Sleep Medicine explicitly warns against the off-label use of atypical antipsychotics (including olanzapine) for chronic primary insomnia due to weak supporting evidence and potential for significant adverse effects 12, 13
• The risk-benefit profile strongly favors other medications with better established efficacy and safety profiles for insomnia treatment 12, 13

Recommended First-Line Treatments for Insomnia

• Benzodiazepine receptor agonists (BzRAs) such as zolpidem, eszopiclone, and zaleplon are recommended as first-line pharmacological treatments for insomnia 14
• Melatonin receptor agonists like ramelteon are also considered appropriate first-line options, particularly for sleep onset insomnia 14

Second and Third-Line Options

• Sedating antidepressants (trazodone, mirtazapine, doxepin, amitriptyline) may be considered when first-line treatments fail or when comorbid depression exists 14
• These medications should be used at lower than antidepressant doses when targeting insomnia symptoms 12, 14

Significant Concerns with Olanzapine Use

• Olanzapine carries substantial risks including weight gain, metabolic syndrome, neurological side effects, and potential for dependence 12

Clinical Approach

• For patients with primary insomnia, start with CBT-I and/or FDA-approved medications (BzRAs or ramelteon) 14
• Only consider olanzapine in specific cases where a patient has a comorbid psychiatric condition that would benefit from its primary mechanism of action 13

Evidence-Based Treatment of Insomnia

First-Line Treatment

• The American Academy of Sleep Medicine recommends Cognitive Behavioral Therapy for Insomnia (CBT-I) as the standard of care for all patients with chronic insomnia before considering pharmacotherapy 15, 16
• CBT-I demonstrates superior long-term outcomes compared to pharmacotherapy, with fewer adverse effects and sustained benefits after treatment discontinuation, as reported by the American Academy of Sleep Medicine 15

First-Line Pharmacotherapy

• The American Academy of Sleep Medicine suggests the use of benzodiazepine receptor agonists (BzRAs), such as zolpidem, eszopiclone, and zaleplon, as first-line pharmacotherapy when CBT-I fails or is unavailable 16
• Low-dose doxepin (3-6 mg) is particularly effective for sleep maintenance insomnia with minimal side effects, according to the American College of Physicians 15

Treatment Approach

• The American College of Physicians recommends offering CBT-I first to all patients with chronic insomnia, and if CBT-I is unavailable or insufficient, prescribing low-dose doxepin (3-6 mg), ramelteon (8 mg), or short-acting BzRA (zolpidem, eszopiclone) 15, 16

Treatment of Insomnia

Guideline-Based Treatment Hierarchy

• The American Academy of Sleep Medicine recommends Cognitive Behavioral Therapy for Insomnia (CBT-I) as the standard of care before any pharmacotherapy, which includes stimulus control, relaxation training, and sleep restriction techniques 17
• The American Academy of Sleep Medicine suggests short/intermediate-acting benzodiazepine receptor agonists (BzRAs), such as zolpidem, eszopiclone, zaleplon, as first-line pharmacotherapy when CBT-I fails or is unavailable 17
• The American Academy of Sleep Medicine recommends ramelteon, a melatonin receptor agonist, for sleep-onset insomnia, particularly suitable for patients with substance use history 17
• For sleep-onset insomnia, the American Academy of Sleep Medicine suggests zaleplon or ramelteon as alternatives to quetiapine, with zaleplon having a very short half-life and minimal residual sedation, and ramelteon having no dependence potential 17
• For sleep-maintenance insomnia, the American Academy of Sleep Medicine recommends eszopiclone or low-dose doxepin 3-6 mg, which is particularly effective with minimal side effects 17
• For patients with substance use history, the American Academy of Sleep Medicine suggests ramelteon, a non-DEA scheduled medication with no dependence potential 17

Nonaddictive Sleep Aids for Insomnia

First-Line Nonaddictive Agents

• The American Academy of Sleep Medicine recommends ramelteon 8 mg at bedtime for sleep-onset insomnia, as it carries zero addiction potential 18, 19
• The American Academy of Sleep Medicine suggests low-dose doxepin 3-6 mg for sleep maintenance insomnia, with minimal side effects and no addiction potential 18

Second-Line Options

• Non-benzodiazepine hypnotics, such as eszopiclone 2-3 mg, zolpidem 10 mg, and zaleplon 10 mg, have significantly lower addiction potential than traditional benzodiazepines 18, 20, 21

Agents to Avoid

• The American Academy of Sleep Medicine explicitly warns against using over-the-counter antihistamines, melatonin supplements, valerian, L-tryptophan, trazodone 50 mg, and atypical antipsychotics as nonaddictive alternatives for insomnia due to lack of efficacy, anticholinergic burden, or significant side effects 18, 22
• Traditional benzodiazepines, such as temazepam and triazolam, are Schedule IV controlled substances with significant dependence potential and should be avoided when nonaddictive alternatives exist 18, 21

Special Populations

• For elderly patients, ramelteon or low-dose doxepin 3 mg are the safest choices due to minimal fall risk and cognitive impairment, and long-acting benzodiazepines should be avoided 20, 21
• For patients with substance use history, ramelteon is the only appropriate choice due to its zero abuse potential and non-DEA-scheduled status 18
• For patients with hepatic impairment, eszopiclone should be reduced to 1 mg maximum, while ramelteon and low-dose doxepin remain safe options 19, 21

Critical Monitoring Requirements

• The American Academy of Sleep Medicine recommends using the lowest effective dose for the shortest duration possible, with regular follow-up to assess continued need for medication, screening for complex sleep behaviors, and maintaining sleep logs to track improvement 20, 21, 22

Sleep Medications for Weight Neutrality and Minimal Next-Day Sedation

Introduction to Sleep Medication Options

• The American Academy of Sleep Medicine recommends low-dose doxepin 3-6 mg for sleep maintenance, noting it has minimal next-day sedation compared to higher antidepressant doses, and is effective for staying asleep with minimal anticholinergic effects and no weight gain 23

Medication Characteristics

• Benzodiazepines, such as temazepam and lorazepam, have long half-lives causing morning sedation and cognitive impairment 24
• Zolpidem causes daytime somnolence in 7% of users and is associated with morning driving impairment 25, 26
• Suvorexant specifically lists daytime somnolence as its primary adverse effect (7% vs 3% placebo) 25, 26

Comparison of Sleep Medications

• Ramelteon does not impair next-day cognitive or motor performance, unlike benzodiazepines and Z-drugs (zolpidem, eszopiclone), which commonly cause morning grogginess and cognitive impairment 25, 26

Non-Narcotic Sleep Medications for Primary Insomnia

First-Line Non-Pharmacologic Treatment

• The American Geriatrics Society recommends Cognitive Behavioral Therapy for Insomnia (CBT-I) components, including stimulus control therapy, sleep restriction therapy, relaxation techniques, and cognitive restructuring, as the gold standard initial treatment for chronic insomnia, demonstrating superior long-term efficacy with sustained benefits after discontinuation compared to pharmacotherapy, with sleep hygiene education alone being insufficient as monotherapy but should supplement other CBT-I components, such as avoiding caffeine/alcohol in the evening, maintaining consistent sleep-wake times, and limiting daytime naps to 30 minutes before 2 PM 27
• Sleep hygiene education should supplement other CBT-I components, including avoiding caffeine/alcohol in the evening, maintaining consistent sleep-wake times, and limiting daytime naps to 30 minutes before 2 PM, as recommended by the American Geriatrics Society 27

Medications to AVOID for Primary Insomnia

• The American Academy of Sleep Medicine explicitly warns against the use of over-the-counter antihistamines, such as diphenhydramine, due to lack of efficacy data, strong anticholinergic effects causing confusion, urinary retention, fall risk in elderly, and daytime sedation, as well as trazodone, benzodiazepines, and atypical antipsychotics, which have significant adverse effects, including weight gain and metabolic syndrome 27
• The American Academy of Sleep Medicine also warns against the use of melatonin supplements, valerian, and L-tryptophan due to insufficient evidence of efficacy, as well as barbiturates and chloral hydrate, which are not recommended for primary insomnia 27

Special Population Considerations

• The American Geriatrics Society recommends ramelteon 8 mg or low-dose doxepin 3 mg as the safest choices for elderly patients (≥65 years) due to minimal fall risk and cognitive impairment, and avoiding long-acting benzodiazepines completely 27

Critical Monitoring and Safety

• The American Geriatrics Society recommends using the lowest effective dose for the shortest duration possible with regular follow-up to assess continued need, screening for complex sleep behaviors, and reassessing after 1-2 weeks to evaluate efficacy on sleep latency, maintenance, and daytime functioning, as well as educating patients about treatment goals, realistic expectations, safety concerns, and potential side effects before prescribing 27

Zopiclone for Sleep Maintenance

Efficacy and Recommendations

• The American Academy of Sleep Medicine recommends non-benzodiazepine receptor agonists, such as zopiclone, as a treatment option for primary insomnia, with a strength of evidence considered moderate to high 28, 29
• The American College of Physicians notes that non-benzodiazepine hypnotics, including zopiclone, are associated with adverse effects such as daytime somnolence, falls, and motor vehicle accidents, although absolute rates are low 30
• The FDA has issued a safety warning regarding the risk of complex sleep behaviors, including sleepwalking and driving while asleep, with all benzodiazepine receptor agonists, including zopiclone 28

Treatment Approach

• Cognitive behavioral therapy for insomnia (CBT-I) should be considered as a first-line treatment before pharmacotherapy, with a strong recommendation based on high-quality evidence 28
• If pharmacotherapy is necessary, zopiclone 7.5 mg represents a valid option for sleep maintenance, particularly in patients who do not tolerate residual effects of other hypnotics, with a moderate strength of evidence 28, 29
• All patients receiving hypnotics should be informed of therapeutic goals, safety concerns, and potential side effects, with a strong recommendation based on high-quality evidence 28

Pregabalin in Insomnia Treatment

Guideline Recommendations

• The American Academy of Sleep Medicine and American College of Physicians do not recommend pregabalin for primary insomnia treatment, as it is not included in any major insomnia treatment guidelines as an approved or evidence-based option 31, 32
• The American Academy of Sleep Medicine recommends Cognitive Behavioral Therapy for Insomnia (CBT-I) as the standard of care for all adults with chronic insomnia, to be initiated before any pharmacotherapy 31, 32
• The American Academy of Sleep Medicine explicitly states that anticonvulsants like pregabalin should only be considered when other options have failed and the patient has a comorbid condition requiring the medication 31, 32

Off-Label Use

• Pregabalin could potentially be considered for insomnia with comorbid neuropathic pain, where the primary indication is pain management, as stated in the Mayo Clinic Proceedings 33

Treatment Approach

• The American Academy of Sleep Medicine and American College of Physicians recommend starting with CBT-I immediately for patients presenting with insomnia, and adding first-line pharmacotherapy if CBT-I is insufficient after 4-8 weeks 31, 32
• The American College of Physicians advises against using pregabalin as first-line treatment for insomnia, as it bypasses evidence-based treatments with superior efficacy and safety profiles 31, 32

Prescription Sleep Aid Recommendations for Insomnia

Medication Selection and Patient Considerations

• The American Academy of Sleep Medicine recommends avoiding benzodiazepines, such as lorazepam, temazepam, and triazolam, as first-line treatment due to higher risk of dependency, falls, cognitive impairment, and respiratory depression compared to non-benzodiazepines 34
• The American Academy of Sleep Medicine also recommends against using trazodone as a first-line treatment for insomnia due to insufficient efficacy data 34
• Antihistamines, such as diphenhydramine and doxylamine, are not recommended for insomnia treatment due to lack of efficacy data, daytime sedation, confusion, urinary retention, and tolerance development after 3-4 days 34
• Antipsychotics, such as quetiapine and olanzapine, are not recommended for insomnia treatment due to insufficient evidence and significant metabolic side effects, including weight gain and metabolic syndrome 34
• For patients with respiratory disorders, such as sleep apnea and COPD, non-benzodiazepines are preferred due to minimal respiratory depression compared to benzodiazepines 34
• The American College of Physicians recommends using the lowest effective dose for the shortest duration possible for insomnia treatment 34

Non-Benzodiazepine/Z-Drug Options for Sleep Maintenance

Primary Recommendation: Low-Dose Doxepin

• The American Academy of Sleep Medicine recommends low-dose doxepin (3-6 mg) as the first choice for sleep maintenance insomnia, demonstrating a 22-23 minute reduction in wake after sleep onset with minimal side effects 35
• Low-dose doxepin (3-6 mg) reduces wake after sleep onset by 22-23 minutes greater than placebo (95% CI: 14-30 minutes) 35
• Total sleep time improvement with low-dose doxepin (3-6 mg) is 26-32 minutes longer than placebo (95% CI: 18-40 minutes) 35
• The American College of Physicians identifies low-dose doxepin as a preferred first-line pharmacotherapy option for sleep maintenance insomnia 35

Alternative Option: Suvorexant (Orexin Receptor Antagonist)

• The American Academy of Sleep Medicine suggests suvorexant as a treatment for sleep maintenance insomnia, though the recommendation is classified as WEAK due to low overall quality of evidence and imprecision 36
• Suvorexant reduces wake after sleep onset by 16-28 minutes greater than placebo (95% CI: 7-43 minutes) 35
• Effective doses of suvorexant are 10 mg, 15/20 mg, and 20 mg, with higher doses showing better efficacy 36
• Total sleep time improvement with suvorexant is 10 minutes longer than placebo (95% CI: 2-19 minutes) 35

Agents to Avoid

• The American Academy of Sleep Medicine states there is insufficient efficacy data for trazodone for insomnia treatment 35
• Melatonin supplements have insufficient evidence of efficacy for sleep maintenance 35
• Valerian and L-tryptophan have insufficient evidence for sleep maintenance 35

Sleep Maintenance Insomnia Treatment Guidelines

First-Line Pharmacotherapy

• The American College of Physicians identifies low-dose doxepin as a preferred first-line option specifically for sleep maintenance, which works through selective H1 histamine receptor antagonism at low doses, avoiding the anticholinergic burden seen with higher antidepressant doses, and has no black box warning for suicide risk at hypnotic doses 37
• Low-dose doxepin has no abuse potential and is the best medication for sleep maintenance insomnia, demonstrating superior efficacy with minimal side effects 37
• Trazodone is explicitly NOT recommended for sleep maintenance insomnia, as The American Academy of Sleep Medicine found no differences in sleep efficiency or discontinuation rates versus placebo, and has low-quality evidence with very short study durations, and adverse effects outweigh minimal benefits 37

Medications to Avoid

• Traditional benzodiazepines should be avoided as first-line treatment due to higher risk of dependency, falls, cognitive impairment, and respiratory depression, particularly in elderly patients and those with respiratory conditions 37
• Over-the-counter antihistamines are NOT recommended due to no efficacy data supporting use for insomnia, strong anticholinergic effects, and tolerance develops after only 3-4 days of continuous use, and The 2019 Beers Criteria carry a strong recommendation to avoid in older adults 37
• Antipsychotics should NOT be used for primary insomnia due to sparse and unclear evidence, significant harms including weight gain, metabolic syndrome, and increased mortality in elderly with dementia 37

Critical Implementation Strategy

• Always combine pharmacotherapy with Cognitive Behavioral Therapy for Insomnia (CBT-I), which demonstrates superior long-term efficacy compared to medications alone, and includes stimulus control, sleep restriction, relaxation techniques, and cognitive restructuring 37
• Use the lowest effective dose for the shortest duration possible, and reassess after 1-2 weeks to evaluate efficacy on sleep maintenance and daytime functioning, and monitor for adverse effects 37
• Patient education is mandatory before prescribing, including discussing treatment goals and realistic expectations, warning about potential side effects and safety concerns, and screening for complex sleep behaviors 37

Insomnia Management Based on Sleep Medication History

Initial Treatment for Patients Without Sleep Medication History

• The American Academy of Sleep Medicine recommends that all adult patients with chronic insomnia should receive cognitive behavioral therapy for insomnia (CBT-I) as the standard treatment before or along with medication therapy 38
• CBT-I has superior long-term effects compared to medication therapy and its effects persist after treatment termination 38
• The American Academy of Sleep Medicine suggests that benzodiazepines (such as lorazepam, clonazepam) should not be recommended as first-line treatment for insomnia 38
• Over-the-counter antihistamines (such as diphenhydramine) are not recommended due to lack of efficacy data and anticholinergic side effects 38

Considerations for Patients With Sleep Medication History

• Patients already taking sleep medications should have their current medication's effectiveness and side effects evaluated, and if ineffective, consider switching to a different medication within the same class or adding a non-benzodiazepine sleep aid, while also starting CBT-I 38
• The American Academy of Sleep Medicine recommends that patients taking benzodiazepines should be switched to non-benzodiazepine sleep aids due to the high risk of dependence, withdrawal symptoms, and cognitive impairment 38, 39
• Benzodiazepines have a higher risk of falls, fractures, cognitive impairment, daytime sedation, and respiratory depression compared to non-benzodiazepine sleep aids 38, 39

Long-Term Management of Insomnia

• The American Medical Association states that there is insufficient evidence to determine the benefits and risks of long-term medication treatment for chronic insomnia 38
• The FDA label indicates that sleep medications are intended for short-term use only 38
• The lowest effective dose should be used for the shortest duration possible, and regular re-evaluation is necessary to determine the continued need for medication therapy 38
• Gradual tapering is recommended when discontinuing medication, and CBT-I can facilitate successful discontinuation 38

Essential Monitoring

• Patients should be monitored for complex sleep behaviors (such as sleep-driving, sleep-walking, sleep-eating), and if observed, the medication should be discontinued immediately [38
• Daytime sleepiness, driving impairment, and fall risk should be evaluated 38
• Suicidal ideation, particularly with zolpidem use, should be monitored (OR 2.08) [38

Important Precautions

• Medications should only be taken when the patient can have at least 7-8 hours of sleep time [38
• Medications should be taken at bedtime and not after meals [38
• Alcohol and other sedatives should not be used concomitantly with sleep medications 39
• Patients should be educated on treatment goals, realistic expectations, safety concerns, and potential side effects 38
• Patients should be warned about the risks of complex sleep behaviors and the importance of reporting any such incidents [38

Next-Step Treatment for Refractory Insomnia After Failure of Initial Medications

Treatment Algorithm and Recommendations

• The American Academy of Sleep Medicine recommends a sequential approach for treating insomnia, starting with short/intermediate-acting BzRAs or ramelteon, followed by alternative BzRAs or orexin antagonists, and finally sedating antidepressants like low-dose doxepin (3-6mg) for sleep maintenance 40
• The American Academy of Sleep Medicine and American College of Physicians mandate that Cognitive Behavioral Therapy for Insomnia (CBT-I) should be initiated before or alongside any pharmacotherapy, as it demonstrates superior long-term efficacy compared to medications alone 40

Implementation and Monitoring

• CBT-I includes stimulus control therapy, sleep restriction therapy, relaxation techniques, and cognitive restructuring, and can be delivered through various formats, all of which show effectiveness 40

Medication‑Induced Sleep Disorders and Their Management

SNRIs and REM‑Sleep Behavior Disorder

• SNRIs such as venlafaxine can induce or worsen REM‑sleep behavior disorder, leading to nighttime restlessness and fragmented sleep in patients receiving these antidepressants. This association is reported by the American Geriatrics Society. 41

Clonazepam Tapering and Withdrawal Risks

• When discontinuing clonazepam, a gradual taper of 0.25–0.5 mg every 1–2 weeks is recommended, with close monitoring for withdrawal‑related seizures (including the risk of status epilepticus). This guidance follows recommendations of the American Academy of Sleep Medicine. 42

• Abrupt cessation of clonazepam may precipitate severe rebound insomnia and seizure activity, underscoring the need for a structured tapering protocol. Evidence from the American Academy of Sleep Medicine supports this precaution. 42

Melatonin Combined with SSRIs for Insomnia: Safety and Efficacy Evidence

Safety of the Combination

• Adding low‑dose melatonin (1–3 mg) to ongoing SSRI therapy does not produce clinically relevant pharmacokinetic or pharmacodynamic interactions, making the combination pharmacologically safe, although melatonin itself is not endorsed for chronic insomnia treatment. – American Academy of Sleep Medicine (weak recommendation) 43, 44

Efficacy of Melatonin for Chronic Insomnia

• The American Academy of Sleep Medicine recommends against the use of melatonin for chronic insomnia in adults, citing a weak recommendation based on current evidence. 43, 44

• A meta‑analysis of three high‑quality randomized trials in adults > 55 years who received 2 mg melatonin versus placebo found no clinically significant reduction in sleep latency. – American Academy of Sleep Medicine, evidence quality very low (imprecision, heterogeneity, possible publication bias) 43, 44

• The same meta‑analysis reported no meaningful increase in total sleep time (mean difference = +17.9 min; 95 % CI = ‑3.8 to +39.5 min). – American Academy of Sleep Medicine, evidence quality very low 43

• No improvement was observed in sleep quality (standardized mean difference = +0.21; 95 % CI = ‑0.36 to +0.77). – American Academy of Sleep Medicine, evidence quality very low 43

• Sleep efficiency did not improve with melatonin compared with placebo. – American Academy of Sleep Medicine, evidence quality very low 43, 44

• Overall, the quality of evidence supporting melatonin’s efficacy for chronic insomnia was rated “very low” due to imprecision, heterogeneity among trials, and potential publication bias. – American Academy of Sleep Medicine 43

Clinical Bottom Line

• While the melatonin‑SSRI combination is pharmacologically safe, current high‑quality evidence indicates no meaningful benefit for chronic insomnia, and guideline bodies advise against its use in this context. – American Academy of Sleep Medicine 43, 44

Management of Chronic Insomnia in Primary Care

Diagnosis and Initial Assessment

• Chronic insomnia is defined as sleep difficulties occurring ≥ 3 nights per week for ≥ 3 months with associated daytime dysfunction. 45
• At the first visit, patients should complete three essential assessments: a general medical/psychiatric questionnaire, the Epworth Sleepiness Scale (to screen for other sleep disorders), and a two‑week sleep diary documenting bedtime, wake times, latency, awakenings, total sleep time, and naps. 46

Focused Clinical Evaluation

Sleep‑History Components

• Document the specific insomnia pattern (difficulty falling asleep, staying asleep, or early‑morning awakening). 47
• Record pre‑sleep conditions such as bedroom environment (light, noise, temperature), bedtime activities (screen use, eating), and mental state (anxious vs. relaxed). 47
• Assess daytime consequences: fatigue is more common than true sleepiness; also evaluate irritability, mood disturbance, cognitive difficulties, and quality‑of‑life impairment affecting work and relationships. 47

Medical and Psychiatric Comorbidities

• Screen for medical conditions that can cause or worsen insomnia, including cardiovascular disease, chronic pain, gastro‑esophageal reflux, asthma/COPD, neurological disorders, and hyperthyroidism. 47
• Psychiatric disorders account for 40‑50 % of chronic insomnia cases, with anxiety and depression being the most frequent. 47

Medication and Substance Review

• Systematically review medications known to disrupt sleep (e.g., certain antidepressants, stimulants, β‑blockers, theophylline, decongestants). 47
• Evaluate caffeine timing/quantity, alcohol use (causes fragmentation despite initial sedation), nicotine, and recreational drug use. 47

Diagnostic Testing

• Polysomnography and Multiple Sleep Latency Testing are not indicated for routine insomnia evaluation; they are reserved for suspected obstructive sleep apnea, periodic limb movement disorder, narcolepsy, or when treatment fails. 48, 46

Treatment Algorithm

First‑Line Therapy – Cognitive Behavioral Therapy for Insomnia (CBT‑I)

• The American Academy of Sleep Medicine recommends immediate initiation of CBT‑I as the foundational treatment; it shows superior long‑term efficacy compared with medications and maintains benefits after discontinuation. 49

Pharmacotherapy (Adjunct to CBT‑I)

• Add pharmacotherapy if CBT‑I alone is insufficient after 2–4 weeks, while continuing CBT‑I. 49

First‑Line Pharmacologic Options

• Sleep‑onset insomnia: short‑acting benzodiazepine‑receptor agonists (e.g., zolpidem 5–10 mg, zaleplon 5–10 mg) or ramelteon 8 mg (preferred for patients with a history of substance use). 49
• Sleep‑maintenance insomnia: low‑dose doxepin 3–6 mg (reduces wake‑after‑sleep‑onset by ~22–23 min) or eszopiclone 2–3 mg. 49

Second‑Line

• If the initial agent fails, switch to an alternative within the same class based on the predominant symptom pattern (sleep‑onset vs. maintenance). 49

Third‑Line

• Sedating antidepressants (trazodone 50–150 mg, mirtazapine, amitriptyline) are reserved for patients with comorbid depression/anxiety or when first‑line agents are ineffective; note that trazodone lacks robust efficacy data as monotherapy for primary insomnia. 49

Agents to Avoid as First‑Line

*All above are discouraged by the American Academy of Sleep Medicine. 49

Patient Education and Follow‑Up

• Prior to prescribing any hypnotic, educate patients about potential side effects and drug interactions. 49
• Reassess every 2–4 weeks initially to evaluate effectiveness, monitor adverse effects (daytime sedation, falls, cognitive changes), and decide on continuation. 49
• When clinically appropriate, taper medications while maintaining CBT‑I support. 49
• For severe, refractory insomnia, chronic hypnotic use may be necessary; it requires ongoing follow‑up, effectiveness assessment, and monitoring for new or worsening comorbidities. Dosing can be nightly, intermittent (≈ 3 nights/week), or as‑needed. 49

Common Pitfalls to Avoid

• Do not prescribe hypnotics as first‑line monotherapy without attempting CBT‑I.
• Do not overlook comorbid psychiatric or chronic pain conditions; these have insomnia prevalence of 50‑75 % and must be treated to resolve insomnia. 47
• Do not continue ineffective medications; if no improvement after 1–2 weeks at therapeutic doses, switch agents rather than increase dose or add multiple drugs. 49
• Do not ignore excessive daytime sleepiness, which is uncommon in primary insomnia and suggests OSA, narcolepsy, or other sleep disorders requiring polysomnography. 47, 46

Evidence‑Based Assessment and First‑Line Management of Insomnia in Middle‑Aged Women

Epidemiology & Clinical Presentation

Contributing Factors & Comorbidities

Diagnostic Evaluation Recommendations

First‑Line Therapeutic Approach

Sleep‑Hygiene Education (Core Component of CBT‑I)